Company / Interest Expense
ADMA Biologics, Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$25.0M
FY2023
5-year range
$13.1M / $25.0M
FY2019-FY2023
Trend
+91.7%
vs FY2022
Sector context
#17 of 44
Health Care
What the data says
At $25M, ADMA Biologics, Inc.'s interest expense ranks #28 of 44 in the Health Care sector. Increased from $13M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2023 with a 5-year CAGR of +35.3%.
Increased from $13M to $25M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +27.8%
- 5-Year CAGR
- +35.3%
- 10-Year CAGR
- -
Sector benchmark
#28 of 44 in Health CareTop 61% of 44This company $25.0M Sector average $291.0M
▼
-91.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +35.3%, indicating consistent growth.
- In FY2023, interest expense increased 91.7% year-over-year.
- Ranks #17 out of 44 companies in the Health Care sector.
- Lowest interest expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $25.0M | +91.7% |
| FY2022 | $13.1M | -0.0% |
| FY2021 | $13.1M | +8.9% |
| FY2020 | $12.0M | +33.3% |
| FY2019 | $9.0M | +62.8% |
| FY2018 | $5.5M | +146.6% |
| FY2017 | $2.2M | +0.0% |
| FY2016 | $2.2M | +74.1% |
As of FY2023 · SEC 10-K · Updated Jul 1, 2026